DEF 14A: Ainos, Inc. Announces 2024 Annual Meeting of Stockholders to be Held on September 27, 2024

Ainos, Inc. will hold its 2024 Annual Meeting of Stockholders on September 27, 2024, to vote on the ratification of the appointment of KCCW Accountancy Corp. as its independent registered public accounting firm, approve the reservation of up to two million shares of common stock as special stock awards, and to transact such other business as may be properly brought before the Annual Meeting and any adjournments thereof.

Summary

• Ainos, Inc. is holding its 2024 Annual Meeting of Stockholders on September 27, 2024.
• The meeting will address the ratification of KCCW Accountancy Corp. as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• Stockholders will also vote on approving the reservation of up to two million shares of common stock as special stock awards, not issued under the 2023 Stock Incentive Plan.
• The record date for determining stockholders eligible to vote is August 5, 2024.
• As of the record date, there were 8,045,406 shares of Common Stock outstanding and entitled to vote at the Annual Meeting.
• The Board of Directors recommends voting FOR the ratification of KCCW Accountancy Corp. and FOR the approval of the reservation of common stock.
• The Board of Directors recommends voting FOR the approval of the adjournment of the Annual Meeting, if necessary or advisable, to solicit additional proxies in favor of the foregoing proposals if there are not sufficient votes to approve the foregoing proposals.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The proposals are routine and the disclosures are factual, leading to a moderately positive sentiment as it reflects ongoing corporate governance.

Positives

• The Board is actively seeking stockholder input on key decisions through the annual meeting.
• The company is following good corporate governance practices by seeking ratification of the independent auditor.

Risks

• Failure to ratify the appointment of KCCW Accountancy Corp. could lead to the Board reconsidering its choice of auditor.
• If the proposal to reserve two million shares of common stock as special stock awards is approved, this could dilute existing shareholders equity.
• If there are not sufficient votes to approve the forgoing proposals, the Company may move to adjourn the Annual Meeting at that time in order to enable our Board to solicit additional proxies.

Future Outlook

The company is seeking to attract and retain key personnel and align their interests with those of the company's shareholders through the use of stock awards.

Management Comments

• Chun-Hsien Tsai, Chief Executive Officer, urges stockholders to review the materials carefully and vote as promptly as possible.

Industry Context

Proxy statements are a standard part of corporate governance, ensuring shareholders have a voice in key decisions. The proposals outlined are typical for a company seeking to maintain compliance and incentivize key personnel.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and stock awards, is generally in line with industry practices for companies of similar size and stage.
• The focus on attracting and retaining key personnel through equity-based compensation is a common strategy in the biotechnology and medical device industries, where talent is critical for success.
• The related party transactions disclosed are not uncommon for companies with significant shareholders and affiliated entities, but they require careful scrutiny to ensure fairness and transparency.

Corporate Governance

Related Party Transactions

• The Company acquired certain intellectual property assets and certain manufacturing, testing, and office equipment from Ainos KY for $26,000,000.
• Ainos KY provided $800,000 in cash in exchange of a promissory note to support working capital of the Company in March 2022.
• The Company entered into a convertible promissory note purchase agreements pursuant to Regulation S of the Securities Act of 1933, as amended, in the total principal amount of $2,000,000 with ASE Test, Inc.
• On May 3, 2024, the Company entered into a convertible note and warrant purchase agreement with the ASE, pursuant to which the Company issued to the ASE a convertible note in the aggregate principal amount of US$9,000,000.
• The Company entered into an exclusive agreement with Ainos KY to serve as the master sales and marketing agent for the Ainos COVID-19 Antigen Rapid Test Kit and COVID-19 Nucleic Acid Test Kit.
• Pursuant to a five-year Product Development Agreement with TCNT, the development expenses incurred were $368,372 and $618,522 for the years ended December 31, 2023 and 2022, respectively.
• The Company sold COVID-19 Antigen Rapid Test Kits to ASEs affiliates, totaling $33,388 and $2,855,205 for the years ended December 31, 2023 and 2022, respectively.

Stakeholder Impact

• Approval of the proposals could impact shareholders through potential dilution from the issuance of new shares.
• Employees may be affected by the approval of the special stock awards, which are intended to attract and retain key personnel.
• The ratification of the auditor ensures the integrity of financial reporting, which benefits all stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on September 27, 2024.
• The company will announce preliminary voting results at the annual meeting.
• The company will disclose voting results in a current report on Form 8-K filed with the SEC within four business days after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, KCCW Accountancy Corp., Common Stock, Ainos, Inc.